Revenio Group Oyj - Managers' transactions

Correction: Revenio Group Corporation: Managers' transactions

 Revenio Group Corporation, Managers' transactions, June 26, 2017 at 16:30

 Revenio Group Corporation: Managers' transactions

 Correction: Number of shares

 Person subject to the notification requirement

 Name:                          Tammela, Pekka

 Position:                      Member of the Board/Deputy member


-------------------------------------------------------------------------------
 Amendment                      Osakemäärä korjattu.


-------------------------------------------------------------------------------
 Issuer

 Name:                          Revenio Group Oyj

 LEI:                           743700I27E0FWSXLKK04


-------------------------------------------------------------------------------
 Transaction details

 Transaction date:              2017-06-21

 Nature of the transaction:     Receipt of a Share-Based Incentive or
                                Remuneration



 Instrument:                    Share

 ISIN:                          FI0009010912



 Volume:                        500

 Unit price:                    0,00000



 Aggregated transactions

 Volume:                        500

 Volume weighted average price: 0.00000

For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932

Distribution:

Nasdaq Helsinki

www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating profit
for continuing operations standing at 30.1%. Revenio Group Corporation is listed
on Nasdaq Helsinki.


[]